Literature DB >> 14871999

A definitive role of RhoC in metastasis of orthotopic lung cancer in mice.

Tetsuro Ikoma1, Tomoyuki Takahashi, Satoshi Nagano, Yun-Mo Li, Yasushi Ohno, Kazuki Ando, Takako Fujiwara, Hisayoshi Fujiwara, Ken-ichiro Kosai.   

Abstract

PURPOSE: Lung cancer is a major cause of cancer death, and its incidence is increasing in the world. Conventional therapies remain less effective for metastases of lung cancer, leading to poor prognosis of this disorder. The present study investigates pathological roles of RhoC in metastasis of lung cancer using a clinically relevant mouse model of lung cancer. EXPERIMENTAL
DESIGN: RhoA, RhoC, dominant-negative Rho (dnRho) or green fluorescent protein gene was retrovirally transduced to murine lung cancer cells. For in vivo study, these transduced cells were intrapulmonary inoculated in syngeneic mice, and subsequently, growth and metastasis were analyzed. Migration and invasion activities were further investigated by in vitro chemotaxic chamber assays. Expression levels and activities of certain matrix metalloproteinases (MMPs) were explored by reverse transcription-PCR and gelatin zymography.
RESULTS: Metastasis of lung cancer in the animal model, as well as in vitro migration and invasion, were significantly enhanced or inhibited by overexpression of RhoC or dnRho, respectively, without affecting the growth of primary tumors. Expression levels of certain MMPs and the activity of MMP-2 were significantly enhanced or suppressed by overexpression of RhoC or dnRho, respectively.
CONCLUSION: RhoC plays a crucial role in metastasis of lung cancer. RhoC does not affect tumor growth but enhances the metastatic nature of lung cancer by not only stimulating cell motility but also up-regulating certain MMPs. Attenuation of RhoC activity may be a potential target in the development of a novel strategy for treating metastasis of lung cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14871999     DOI: 10.1158/1078-0432.ccr-03-0275

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  43 in total

1.  RhoC promotes metastasis via activation of the Pyk2 pathway in prostate cancer.

Authors:  Megumi Iiizumi; Sucharita Bandyopadhyay; Sudha K Pai; Misako Watabe; Shigeru Hirota; Sadahiro Hosobe; Taisei Tsukada; Kunio Miura; Ken Saito; Eiji Furuta; Wen Liu; Fei Xing; Hiroshi Okuda; Aya Kobayashi; Kounosuke Watabe
Journal:  Cancer Res       Date:  2008-09-15       Impact factor: 12.701

2.  The role of RhoC in the proliferation and apoptosis of hepatocellular carcinoma cells.

Authors:  Shuli Xie; Mingguang Zhu; Guoyue Lv; Qiang Zhang; Guangyi Wang
Journal:  Med Oncol       Date:  2011-06-15       Impact factor: 3.064

3.  p38γ promotes breast cancer cell motility and metastasis through regulation of RhoC GTPase, cytoskeletal architecture, and a novel leading edge behavior.

Authors:  Devin T Rosenthal; Harish Iyer; Silvia Escudero; Liwei Bao; Zhifen Wu; Alejandra C Ventura; Celina G Kleer; Ellen M Arruda; Krishna Garikipati; Sofia D Merajver
Journal:  Cancer Res       Date:  2011-08-23       Impact factor: 12.701

4.  Down regulation of RhoC by microRNA-138 results in de-activation of FAK, Src and Erk1/2 signaling pathway in head and neck squamous cell carcinoma.

Authors:  Mozaffarul Islam; Jharna Datta; James C Lang; Theodoros N Teknos
Journal:  Oral Oncol       Date:  2014-02-22       Impact factor: 5.337

5.  RhoC involved in the migration of neural stem/progenitor cells.

Authors:  Can Zhang; Xuemei Ge; Kenghoe Lok; Lu Zhao; Ming Yin; Ze-Jian Wang
Journal:  Cell Mol Neurobiol       Date:  2014-01-11       Impact factor: 5.046

6.  RhoC, vascular endothelial growth factor and microvascular density in esophageal squamous cell carcinoma.

Authors:  Zhi-Hua Zhao; Yan Tian; Jian-Pin Yang; Jun Zhou; Kui-Sheng Chen
Journal:  World J Gastroenterol       Date:  2015-01-21       Impact factor: 5.742

7.  Tumor suppressor microRNA-493 decreases cell motility and migration ability in human bladder cancer cells by downregulating RhoC and FZD4.

Authors:  Koji Ueno; Hiroshi Hirata; Shahana Majid; Soichiro Yamamura; Varahram Shahryari; Z Laura Tabatabai; Yuji Hinoda; Rajvir Dahiya
Journal:  Mol Cancer Ther       Date:  2011-11-04       Impact factor: 6.261

8.  Type I collagen receptor (alpha2beta1) signaling promotes prostate cancer invasion through RhoC GTPase.

Authors:  Christopher L Hall; Cara W Dubyk; Tracy A Riesenberger; Daniel Shein; Evan T Keller; Kenneth L van Golen
Journal:  Neoplasia       Date:  2008-08       Impact factor: 5.715

9.  A mediator of Rho-dependent invasion moonlights as a methionine salvage enzyme.

Authors:  Yukihito Kabuyama; Elizabeth S Litman; Paul D Templeton; Sandra I Metzner; Eric S Witze; Gretchen M Argast; Stephen J Langer; Kirsi Polvinen; Yiqun Shellman; Daniel Chan; John B Shabb; James E Fitzpatrick; Katheryn A Resing; Marcelo C Sousa; Natalie G Ahn
Journal:  Mol Cell Proteomics       Date:  2009-07-20       Impact factor: 5.911

10.  Silencing of RhoA and RhoC expression by RNA interference suppresses human colorectal carcinoma growth in vivo.

Authors:  Haibo Wang; Gang Zhao; Xiangping Liu; Aihua Sui; Kun Yang; Ruyong Yao; Zongbao Wang; Qiang Shi
Journal:  J Exp Clin Cancer Res       Date:  2010-09-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.